Influence of neurotoxins and oxidative stress on the onset end progression of Parkinson's disease

Journal of Neurology, Supplement

Volumn 247, Issue 2, 2000, Pages 82-94

  Foley, Paul ^a   Riederer, Peter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Neurodegeneration; Oxidative stress; Parkinson's disease; Reactive oxygen species

Indexed keywords

ADVANCED GLYCATION END PRODUCT; DOPAMINE; HYDROXYL RADICAL; IRON; NEUROMELANIN; NEUROTOXIN; NITRIC OXIDE; PARAQUAT; REACTIVE OXYGEN METABOLITE;

AUTOPSY; CONFERENCE PAPER; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GLIA CELL; HUMAN; LEWY BODY; METABOLISM; NERVE CELL NECROSIS; NERVE DEGENERATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN MODIFICATION; SUBSTANTIA NIGRA;

ANIMALS; BRAIN; DISEASE PROGRESSION; HUMANS; NEUROTOXINS; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 0034009915     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (140)

1. Adams JD, Odunze IN (1991) Biochemical mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Biochem Pharmacol 41: 1099-1105
2. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B (1997) Oxidative DNA damage in the parkinsonian brain: a selective increase in 8-hydroxysuanine in substantia nigra? J Neurochem 69:1196-1203
3. Ambani LM, Van Woert MH, Murphy S (1975) Brain peroxides and catalase in Parkinson's disease. Arch Neurol 32:114-118
4. Anglade P, Agid Y, Hirsch EC, Vyas S (1997) Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol Histopathol 12:603-610
5. Asanuma M, Hirata H, Cadet JL (1998) Attenuation of 6-hydroxydopamine-induced dopaminergic nigrostriatal lesions in Superoxide dismutase transgenic mice. Neuroscience 85:907-917
6. Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J (1985) Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 339: 1213-1216
7. Baron JA (1986) Cigarette smoking and Parkinson's disease. Neurology 36:1490-1496
8. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman PA (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and Superoxide. Proc Nat Acad Sci USA 87:1620-1624
9. Ben-Shachar D, Eshel G, Finberg JPM, Youdim MBH (1991) The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal neurons. J Neurochem 56:1441-1444
10. Ben-Shachar D, Youdim MBH (1991) Intranigral iron injection induces behavioral and biochemical "Parkinsonism" in rats. J Neurochem 57:2133-2135
11. Berman SB, Hastings TH (1997) Inhibition of glutamate transport in synaptosomes by dopamine oxidation and reactive oxygen species. J Neurochem 69:1185-1195
12. Blunt SB, Jenner P, Marsden CD (1993) Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 8:129-133
13. Braak H, Braak E, Yilmazer D, Schultz C, de Vos RAI, Jansen ENH (1995) Nigral and extranigral pathology in Parkinson's disease. J Neural Transm [Suppl] 46:15-32
14. Bringmann G, Feineis D, Grote C, God R, Clement HW, Sontag KH, Janetzky B, Reichmann H, Rausch WD, Riederer P, Wesemann W (1998) Highly halogenated tetrahydro-β-carbolines as a new class of dopaminergic neurotoxins. In: Moser A (ed) Pharmacology of endogenous neurotoxins. A handbook. Birkhäuser, Boston pp 151-169
15. Bringmann G, God R, Fähr S, Feineis D, Fornadi K, Fornadi F (1999) Identification of the dopaminergic neurotoxin 1-trichloromethyl-1,2,3,4-tetrahydro-β-carboline in human blood after intake of the hypnotic chloral hydrate. Anal Biochem 270:167-175
16. Buccala R, Cerami A (1992) Advanced glycosylation: chemistry, biology and implications for diabetes and aging. Adv Pharmacol 23:1-34
17. Calingasan NY, Gandy SE, Gibson GE (1997) Thiamine deficiency alters APP but not presenilin-1 immunoreactivity in vulnerable brain regions. Neuroreport 8:2631-2634
18. Calne DB, Eisen AA (1989) The relationship between Alzheimer's disease, Parkinson's disease and motoneuron disease. Can J Neurol Sci 16:547-550
19. Castellani R, Smith MA, Richey PL, Perry G (1996) Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res 737:195-200
20. Chandrasekaran K, Rapoport SI, Brady DR, Stoll J (1992) Localisation of cytochrome oxidase (COX) activity and COX mRNA in the hippocampus and entorhinal cortex of the monkey brain: correlation with specific neuronal pathways. Brain Res 579:333-336
21. Chen X, Xia Y, Alford M, DeTeresa R, Hansen L, Klauber MR, Katzman R, Thai L, Masliah E, Saitoh T (1995) The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease. Ann Neurol 38: 653-658
22. Cleeter MWJ, Cooper JM, DarleyUsmar VM, Moncada S, Schupira AHV (1994) Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide: implications for neurodegenerative disorders. Acta Biochem Biophys 288:481-487
23. Cleeter MWJ, Cooper JM, Schapira AHV (1992) Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem 58:786-789
24. Collins MA, Neafsey EJ (1985) β-Carboline analogues of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism. Neurosci Lett 55:179-184
25. Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P (1995) A quantitative analysis of isoferritins in select regions of aged, parkinsonian and Alzheimer's diseased brains. J Neurochem 65:717-724
26. D'Amato RJ, Alexander GM, Schwartzman RJ, Kitt CA, Price DL, Snyder SH (1987) Evidence for neuromelanin involvement in MPTP-induced neurotoxicity. Nature 327: 324-326
27. Damier P, Hirsch E, Javoy-Agid F, Zhang P, Agid Y (1993) Glutathione peroxidase, glial cells and Purkinson's disease. Neuroscience 52:1-6
28. Davey GP, Peuchen S, Clark JB (1998) Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration. J Biol Chem 273:12753-12757
29. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ (1979) Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiat Res 1:249-254
30. Dawson TM, Dawson VL, Snyder SH (1992) A novel neuronal messenger molecule in brain: the free radical, nitric oxide. Ann Neurol 32:297-311
31. De Michele G, Filla A, Volpe G, Gogliettino A, Ambrosio G, Campanella G (1996) Etiology of Parkinson's disease. The role of environment and heredity. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology. Volume 69: Parkinson's disease. LippincottRaven, Philadelphia, pp 19-24
32. Dexter DT, Carayon A, Javoy-Agid F (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114:1953-1975
33. Dexter DT, Cater CJ, Wells FR, Javoy-Agid, F Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantial nigra is increased in Parkinson's disease. J Neurochem 52:381-389
34. Dexter DT, Holley AE, Flitter WD, Slater TF, Wells FR, Daniel SE, Lees AJ, Jenner P, CD Marsden (1994) Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 9:92-97
35. Dexter DT, Sian J, Rose S, Hindmarsh JS, Mann VM, Cooper JM, Wells FR, Daniel SE, Lees AJ, Schapira AHV, Jenner P, Marsden CD (1994) Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 35:38-44
36. Dexter DT, Ward RJ, Wells FR, Daniel SE, Lees AJ, Peters IJ, Jenner P, Marsden CD (1992) α-Tocopherol levels in brain are not altered in Parkinson's disease. Ann Neurol 32:591-593
37. Dexter DT, Wells FR, Agid FJ (1987) Increased nigral iron content in postmortem parkinsonian brain. Lancet 341:1219-1220
38. Di Monte DA (1991) Mitochondrial DNA and Parkinson's disease. Neurology 41 [Suppl 2]:38-42
39. Di Monte DA, Royland JE, Irwin I, Langsten JW (1996) Astrocytes as the site for bioactivation of neurotoxins. Neurotoxicology 17:697-703
40. Dostert P, Strolin-Benedetti M, Dordain G (1988) Dopamine-derived alkaloids in alcoholism and in Parkinson's and Huntington's disease. J Neural Transm 74:61-74
41. Double KL, Maywald M, Schmittel M, Riederer P, Gerlach M (1997) In vitro studies of ferritin iron release and neurotoxicity. J Neurochem 70: 2492-2499
42. Durlach J, Bac P, Durlach V, Durlach A, Bara M, Guiet-Bara A (1997) Are age-related neurodegenerative diseases linked with various types of magnesium depletion? Magnes Res 10:339-353
43. 125I-ferrotransferrin binding sites in the mesencephalon of control subjects and patients with Parkinson's disease. J Neurochem 60:2238-2241
44. Faucheaux BA, Nillesse N, Damier P, Spik G, Mouatt-Prigent A, Pierce A, Leveugle B, Kubis N, Hauw JJ, Agid Y, Hirsch EC (1995) Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson's disease. Proc Nat Acad Sci USA 92:9303-9307
45. Forno LS, Langston JW (1993) Lewy bodies and aging: relation to Alzheimer's and Parkinson's diseases. Neurodegeneration 2:19-24
46. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63:793-807
47. Gerlach M, Riederer P (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987-1041
48. Gerlach M, Xiao AY, Heim C, Lan J, God R, Feineis D, Bringmann G, Sontag KH (1998) 1-Trichloromethyl-1,2,3,4-tetrahydro-b-carboline increases extracellular serotonin and stimulates hydroxyl radical production in rats. Neurosci Lett 257:17-20
49. Good P, Olanow CW, Perl DP (1992) Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease. A LAMMA study. Brain Res 593: 343-346
50. Götz ME, Künig G, Riederer P, Youdim MBH (1994) Oxidative stress. Free radical production in neural degeneration. Pharmacol Ther 63:37-122
51. Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633-643
52. Gu M, Owen AD, Toffa SE, Cooper JM, Dexter DT, Jenner P, Marsden CD, Schapira AHV (1998) Mitochondrial function, GSH and iron in neurodegeneration and Lewy body disease. J Neurol Sci 158:24-29
53. Gutteridge JM, Quinlan GJ, Clark I, Halliwell B (1985) Aluminum salts accelerate peroxidation of membrane lipids stimulated by iron salts. Biochim Biophys Acta 835:441-447
54. Halliday GM, Blumberg PC, Cotton RGH, Blessing WW, Geffen LB (1990) Loss of brainstem serotoninand substance P-containing neurons in Parkinson's disease. Brain Res 510:104-107
55. Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59:1609-1623
56. Hattori N, Tanaka M, Ozawa T, Mizuno Y (1991) Immunohistochemical studies on complexes I, II, III and IV of mitochondria in Parkinson's disease. Ann Neurol 30:563-571
57. Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y (1991) Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem 56:446-451
58. Hunot S, Boissièrre F, Faucheux B, Brugg B, Mouatt-Prigend A, Agid Y, Hirsch EC (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72:355-363
59. Irwin I, Langston JW (1995) Endogenous toxins as potential etiologic agents in Parkinson's disease. In: Ellenberg JH, Koller WC, Langston JW (eds) Etiology of Parkinson's disease. Marcel Dekker, New York, pp 153-201
60. Itoh K, Weis S, Mehraein P, Muller-Hocker J (1997) Defects of cytochrome c oxidase in the substantia nigra of Parkinson's disease: an immunohistochemical and morphometric study. Mov Disord 12:9-16
61. Janetzky B, God R, Bringmann G, Reichmann H (1995) 1-Trichloromethyl-1,2,3,4-tetrahydro-β-carboline, a new inhibitor of complex I. J Neural Transm [Suppl] 46:265-273
62. Jellinger KA (1990) New developments in the pathology of Parkinson's disease. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH (eds) Advances in neurology. Volume 53: Parkinson's disease: anatomy, pathology and therapy. Raven Press, New York, pp 1-16
63. Jellinger KA (1991) Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 14:153-197
64. Jellinger K, Youdim MBH, BenShachar D, Stachelberger H, Riederer P, Rumpelmair G, Kienzl E (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J Neurochem 59:1168-1171
65. Jenner P (1998) Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 13: [Suppl 1]:24-34
66. Jenner P, Olanow CW (1996) Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders. In: Olanow CW, Jenner P, Youdim M (eds) Neurodegeneration and neuroprotection in Parkinson's disease. Academic, London, pp 24-45
67. Kawai H, Makino Y, Hirobe M, Ohta S (1998) Novel endogenous 1,2,3,4-tetrahydroisoquinoline derivatives: uptake by dopamine transporter and activity to induce parkinsonism. J Neurochem 70:745-751
68. Kim HJ, Joon HR, Washington S, Chang II, Oh YJ, Surh YJ (1997) DNA strand scission and PC12 cell death induced by salsolinol and copper. Neurosci Lett 238:95-98
69. Kish SJ, Morito CH, Hornykiewicz O (1985) Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett 58:343-346
70. Kondo I, Yamamoto M (1998) Genetic polymorphism of paraoxonase 1 (PON 1) and susceptibility to Parkinson's disease. Brain Res 806:271-273
71. Kuhn W, Müller T (1997) Hypersusceptibilität gegen Xenobiotika. Die potentielle Bedeutung ökogenetischer Faktoren für die Ätiologie des Morbus Parkinson. In: Fischer PA (ed) Parkinson-Krankheit. Entwicklungen in Diagnostik und Therapie. Schattauer, Stuttgart, pp 87-93
72. Kuhn W, Müller T, Grosse H, Rommelspacher H (1996) Elevated levels of harman and norharman in cerebrospinal fluid of parkinsonian patients. J Neural Transm 103:1435-1440
73. Landi MT, Ceroni M, Martignoni E, Bertazzi PA, Caporaso NE, Nappi G (1996) Gene-environment interaction in Parkinson's disease. The case of CYP2D6 polymorphism. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology. Volume 69: Parkinson's disease. LippincottRaven Publishers, Philadelphia, pp 61-72
74. Langston JW (1996) The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology 47 [Suppl 3]:S153-S160
75. Leveugle B, Faucheux BA, Bouras C, Nillesse N, Spik G, Hirsch EC, Agid Y, Hof PR (1996) Immunohistochemical analysis of the iron binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases. Acta Neuropathol 91:566-572
76. Mann VM, Cooper JM, Daniel SE, Srai K, Jenner P, Marsden CD, Schapira AHV (1994) Complex I, iron and ferritin in Parkinson's disease substantia nigra. Ann Neurol 36:876-881
77. Martilla RJ, Lorentz H, Rinne UK (1988) Oxygen toxicity protecting enzymes in Parkinson's disease: increase of Superoxide dismutase-like activity in the substantial nigra and basal nucleus. J Neurol Sci 86:321-331
78. Maruyama W, Naoi M, Kasamatsu T, Hashizume Y, Takahashi T, Kohda K, Dostert P (1997) An endogenous dopaminergic neurotoxin, N-methyl-(R)-salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells. J Neurochem 69:322-329
79. Maruyama W, Sobue G, Matsubara K, Hashizume Y, Dostert P, Naoi M (1997) A dopaminergic neurotoxin, 1(R),2(N)-dimethyl-6.7-dihydroxy-1,2,3,4-dihydroisoquinoline, N-methyl(R)salsolinol, and its oxidation product, 1,2( N)-dimethyl-6,7-dihydroxyisoquinolinium ion, accumulate in the nigro-striatal system of the human brain. Neurosci Lett 223:61-64
80. Matsubara K, Gonda T, Sawada H, Uezono T, Kobayashi Y, Kawamura T, Ohtaki K, Kimura K, Akaike A (1998) Endogenously occurring β-carboline induces parkinsonism in nonprimate animals: a possible causative protoxin in idiopathic Parkinson's disease. J Neurochem 70:727-735
81. + analogs, in the lumbar cerebrospinal fluid of patients with Parkinson's disease. Neurology 45:2240-2245
82. McNaught KS, Carrupt PA, Altomare C, Cellemare S, Carotti A, Testa B, Jenner P, Marsden CD (1998) Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease. Biochem Pharmacol 56:921-933
83. McNaught KS, Thull U, Carrupt PA, Altomare C, Cellemare S, Carotti A, Testa B, Jenner P, Marsden CD (1996) Inhibition of [3H]dopamine uptake into striatal synaptosomes by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1.2,3,6-tetrahydropyridine. Biochem Pharmacol 52:29-34
84. Menegon A, Board BG, Blackburn AC, Mellick GD, Le Couteur DG (1998) Parkinson's disease, pesticides and glutathione transferase polymorphisms. Lancet 352:1344-1346
85. Merad-Boudia M, Nicole A, SantiardBaron D, Saille C, Ceballos-Picot I (1998) Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: relevance to Parkinson's disease. Biochem Pharmacol 56:645-655
86. Mizuno Y, Yoshino H, Ikebe S, Hattori N, Koyabashi T, ShimodaMatsubayashi S, Matsumine H, Kondo T (1998) Mitochondrial dysfunction in Parkinson's disease. Ann Neurol 44 [Suppl 1]:S99-S109
87. Mochizuki H, Goto K, Mori H, Mizuno Y (1996) Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci 137:120-123
88. Morikawa N, Naoi M, Maruyama W, Ohta S, Kotake Y, Kawai H, Niwa T, Dostert P, Mizuno Y (1998) Effects of various tetrahydroisoquinoline derivatives on mitochondrial respiration and the electron transfer complexes. J Neural Transm 105:677-688
89. Mufson EJ, Brandubur MM (1994) Sparing of NADPH-diaphorase striatal neurons in Parkinson's and Alzheimer's diseases. Neuroreport 5: 705-708
90. Münch G, Gerlach M, Sian J, Wong A, Riederer P (1998) Advanced glycation end products in neurodegeneration: more than early markers of oxidative stress? Ann Neurol 44 [Suppl 1]:S85-S88
91. Münch G, Thome J, Foley P, Schinzel R, Riederer P (1997) Advanced glycation end products in ageing and disease. Brain Res Rev 23:134-143
92. Nagatsu T (1997) Isoquinoline neurotoxins in the brain of Parkinson's disease. Neurosci Res 29:99-111
93. Naoi M, Maruyama W, Dostert P, Hashizume Y (1997) N-melhyl-(R)salsolinol as a dopaminergic neurotoxin: from an animal model to an early marker of Parkinson's disease. J Neural Transm Suppl 50:89-105
94. Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash G (1994) Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res 660:8-18
95. Ozawa T, Hayakawa M, Katsumata K, Yoneda M, lkebe S, Mizuno Y (1997) Fragile mitochondrial DNA: the missing link in the apoptotic neuronal cell death in Parkinson's disease. Biochem Biophys Res Commun 235:158-161
96. Pearce RKB, Owen A, Daniel S, Jenner P, Marsden CD (1997) Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm 104:661-677
97. Perry TL, Goden DV, Hansen S (1982) Parkinson's disease: a disorder due to nigral glutathione deficiency. Neurosci Lett 33:305-310
98. Pileblad E, Magnusson T, Fornstedt B (1996) Reduction of brain glutathione by L-buthionine sulfoximine potentiates the dopamine-depleting action of 6-hydroxydopamine in rat striatum. J Neurochem 52:978-980
99. Przedborski S, Jackson-Lewis V, Muthane U, Jiang H, Ferreira M, Naini AB, Fahn S (1993) Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 34:715-723
100. Przedborski S, Kostic V, Jackson-Lewis V, Naini AB, Simonetti S, Fahn S, Carlson E, Epstein CJ, Cadet JL (1992) Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to MPTP-induced neurotoxicity. J Neurosci 12:1658-1667
101. Przuntek H, Müller T, Kuhn W, Hoffmann V (1997) Ist Apoptose, ein zentraler Mechanismus der Neurodegeneration, durch Selegiline beeinflußbar? In: Fischer PA (ed) Parkinson-Krankheit. Entwicklungen in Diagnostik und Therapie. Schattauer, Stuttgart, pp 259-274
102. Radi R, Beckman JS, Bush KM, Freeman BA (1991) Peroxynitrite-induced membrane peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 288:481-487
103. Reichmann H, Lestienne P, Jellinger K, Riederer P (1993) Parkinson's disease and the electron transport chain in post mortem brain. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y (eds) Advances in Neurology. Volume 60: Parkinson's disease: from basic research to treatment. Raven, New York, pp 297-299
104. Reif DW, Simmons RD (1990) Nitric oxide mediates iron release from ferritin. Arch Biochem Biophys 283: 537-541
105. Reiter RJ (1998) Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 56: 359-384
106. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brains. J Neurochem 52:515-520
107. Riederer P, Youdim MBH (eds) (1993) Iron in central nervous system disorders. Springer, Vienna
108. Robbins JH, Otsuka F, Nee LE (1985) Parkinson's disease and Alzheimer's disease: hypersensitivity to X-rays in cultured cell lines. J Neurol Neurosurg Psychiatry 48:916-923
109. Robles M, Choi BH, Han B, Santa Cruz K, Kim RC (1998) Repininduced neurotoxicity in rodents. Exp Neurol 152:129-136
110. Robles M, Wang N, Kim R, Choi BH (1997) Cytotoxic effects of repin, a principal sesquiterpene lactone of Russian knapweed. J Neurosci Res 47:90-97
111. Ross BM, Moszczynska A, Ehrlich J, Kish SJ (1998) Low activity of key phospholipid catabolic and anabolic enzymes in human substantia nigra: possible implications for Parkinson's disease. Neuroscience 83:791-798
112. Rubanyi GM, Ho EH, Cantor EH, Lumma WC, Botelho LH (1991) Cytoprotective function of nitric oxide: inactivation of superoxide radicals produced by human leukocytes. Biochem Biophys Res Commun 181: 1392-1397
113. Saggu H, Cooksey J, Dexter D, Wells FR, Lees A, Jenner P, Marsden CD (1989) A selective increase in particulate superoxide dismutase activity in Parkinsonian subslantia nigra. J Neurochem 53:692-697
114. Sanchez-Ramos JR, Övervik E, Ames BN (1994) A marker of oxyradicalmediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 3:197-204
115. Schapira AHV (1996) Neurotoxicity and the mechanisms of cell death in Parkinson's disease. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology. Volume 69: Parkinson's disease. LippincottRaven Publishers. Philadelphia, pp 161-165
116. Schapira AHV (1999) Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedrich's ataxia. Biochim Biophys Acta 1410:159-170
117. Schapira AHV, Gu M, Taanman JW, Tabrizi SJ, Seaton T, Cleeter M, Cooper JM (1998) Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann Neurol 44 [Suppl 1]:S89-S98
118. Schapira AHV, Mann VM, Cooper JM. Dexter DT, Daniel SE, Jenner P, Clark JB, Marsden CD (1990) Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 55:2142-2145
119. Sengstock GJ, Olanow CW, Dunn AJ, Barone S, Arendash GW (1994) Progressive changes in striatal dopaminergic markers, nigral volume and rotational behavior following iron infusion into rat substantia nigra. Exp Neurol 130: 82-94
120. Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD (1994) Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 36: 356-361
121. Smith TA, Prayson RA (1996) Lewy body disease. South Med J 89:1174-1180
122. Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142:128-130
123. Sofic E, Riederer P, Heinsen H, Beckman H, Reynolds GP, Hebenstreit G, Youdim MBH (1988) Increased iron(III) and total iron content in post mortem substantia nigra of Parkinsonian brain. J Neural Transm 74:199-205
124. Spencer PS, Butterfield PG (1995) Environmental agents and Parkinson's disease. In: Ellenberg JH, Koller WC, Langston JW (eds) Etiology of Parkinson's disease. Marcel Dekker, New York, pp 319-365
125. Spencer JPE, Jenner A, Aruoma OI, Evans PJ, Kaur H, Dexter DT, Jenner P, Lees AJ, Marsden CD, Halliwell B (1994) Intense oxidative DNA damage promoted by L-dopa and its metabolites: implications for neurodegenerative disease. FEBS Lett 353: 246-250
126. Spencer-Smith T, Parker WD, Bennett JP (1994) L-Dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity? Neuroreport 5:1009-1011
127. Spina MB, Cohen G (1989) Dopamine turnover and glutathione oxidation: implications for Parkinson's disease. Proc Nat Acad Sci USA 88:1398-1400
128. Temlet JA, Landsberg JP, Watt F, Grime GW (1994) Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. J Neurochem 62:134-146
129. Toffa S, Kunikowska GM, Zeng BY, Jenner P, Marsden CD (1997) Chronic glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration. J Neural Transm [Park Dis Sect] 104:67-75
130. Tompkins MM, Basgall EJ, Zamrini E, Hill WD (1997) Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am J Pathol 150:119-131
131. von Voigtlander PF, Fici GJ, Althaus JS (1998) Pharmacological approaches to counter the toxicity of Dopa. Amino Acids 14:189-196
132. Walkinshaw G, Waters CM (1995) Induction of apoptosis in catecholaminergic PC12 cells by L-dopa: implications for the treatment of Parkinson's disease. J Clin Invest 95:2458-2464
133. Wallace DC (1992) Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science 256: 628-632
134. Wallace DC (1992) Diseases of the mitochondrial DNA. Ann Rev Biochem 61:1175-1212
135. Wesemann W, Blaschke S, Solbach M, Grote C, Clement HW, Riederer P (1994) Intranigral injected iron progressively reduces striatal dopamine metabolism. J Neural Transm [Park Dis Sect] 8:209-214
136. Wüllner U, Löschmann PA, Schulz JB. Schmid A, Dringen R, Eblen F, Turski L, Klockgether T (1996) Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones. Neuroreport 7:921-923
137. Yoritaki A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson's disease. Proc Nat Acad Sci USA 93:2696-2713
138. Yoshida E, Mokuno K, Aoki SI, Takahashi A, Riku S, Murayama T, Yanagi T, Kato K (1994) Cerebrospinal fluid levels of Superoxide dismutases in neurological diseases detected by sensitive enzyme immunoassays. J Neurol Sci 124:25-31
139. Yoshida T, Tanaka M, Sotomatsu A, Hirai S, Okamoto K (1998) Activated microglia cause iron-dependent lipid peroxidation in the presence of ferritin. Neuroreport 9:1929-1933
140. Youdim MBH, Ben-Shachar D, Riederer P (1994) The enigma of neuromelanin in Parkinson's disease substantia nigra. J Neural Transm [Suppl] 43:113-132